Beam Therapeutics (BEAM) Accumulated Depreciation (2019 - 2026)

Beam Therapeutics (BEAM) has reported Accumulated Depreciation for 8 consecutive years, with $99.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Depreciation rose 28.46% year-over-year to $99.7 million; the TTM figure through Mar 2026 stood at $99.7 million (up 28.46% YoY), while the FY2025 annual figure was $94.1 million, up 30.54% from the prior year.
• Accumulated Depreciation climbed to $99.7 million in Q1 2026 per BEAM's latest filing, from $94.1 million in the prior quarter.
• Across five years, Accumulated Depreciation topped out at $99.7 million in Q1 2026 and bottomed at $19.3 million in Q1 2022.
• Historically, Accumulated Depreciation has averaged $56.9 million across 5 years, with a median of $55.6 million in 2024.
• Annual changes were most pronounced in 2022 — Accumulated Depreciation surged 93.95% — and 2026, when it advanced 28.46%.
• Beam Therapeutics' Accumulated Depreciation stood at $30.2 million in 2022, then surged by 66.33% to $50.2 million in 2023, then surged by 43.69% to $72.1 million in 2024, then surged by 30.54% to $94.1 million in 2025, then gained by 5.95% to $99.7 million in 2026.
• Business Quant data shows BEAM's Accumulated Depreciation at $99.7 million in Q1 2026, $94.1 million in Q4 2025, and $88.6 million in Q3 2025.